Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Robert L. Ray who wrote (4551)	6/24/1998 11:00:00 PM
From: General Crude	Respond to of 6136

Short Interest Item Ticker Company Name Month Shares Short Avg Daily Volume Ratio* Remark 1 AGPH Agouron Pharmaceutical 05/98 9,519,722 854,850 11.14 04/98 7,793,150 628,366 12.40 03/98 7,714,800 540,761 14.27 02/98 8,203,460 606,325 13.53

To: Robert L. Ray who wrote (4551)	7/7/1998 6:56:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 6136

To All, In looking at AGPH's 10-K from last year I noticed in the pipeline chart that they are in phase one trials with an MMP inhibitor for "inflammatory diseases". The name of the compound wasn't mentioned but I assume it was AG3340 which of course is also their cancer compound. Other than the 10-k I've not read anything about AG3340 being in clinical trials for other indications. Later on the 10-K mentions that the MMP clinical for arthritis was being conducted by Roche. So what I'm wondering now is AG3340 as an arthritis agent still being actively pursued by AGPH?... Are any clinicals going on this or did this project die out along with the dissolution of the Roche cancer product agreements?